Arrhythmias & electrophysiology

Cost-effectiveness of digoxin versus beta blockers in permanent atrial fibrillation: the Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF) randomised trial

HeartPublished randomised, open-label, blinded, endpoint trial

Primary result · Costs per patient per yearResult — go to the resultMean saving £530.41 per patient per year 95% CI -£848.06 to -£249.38

Authors' conclusion

Digoxin is a less costly option when compared with beta-blockers for control of heart rate in suitable patients with permanent AF, with larger cost-effectiveness studies warranted to advise on national and global policy-making.

Study context

Population
Patients with permanent atrial fibrillation (AF) and symptoms of heart failurerandomised, mean age 76 (SD 8) years, 46% women, 149 had complete data and survived to 12-month follow-up
Participants
160 patients
Comparison
Low-dose digoxin with beta-blockers
  • Digoxinn = 73
  • Beta blockersn = 76
Methodological detailsembedded in the UK National Health Service (NHS), trial-based cost-utility analysis, healthcare perspective over 12 months
  • Embedded in the UK National Health Service (NHS)
  • Trial-based cost-utility analysis
  • Healthcare perspective over 12 months

Primary result

Costs per patient per year · 12 months

Mean saving

£530.41 per patient per year

95% CI -£848.06 to -£249.38

P = 0.001

As reported in the abstract

Further findings

Quality-adjusted life years (QALYs) · 12 months

No significant difference in QALYs
0.013; 95% CI −0.033 to 0.052, p=0.56

Probability of digoxin being cost-effective at £20 000 per-QALY willingness to pay threshold

Probability digoxin cost-effective vs beta-blockers
94%
Potential annual savings to the NHS
£102 million/year (95% CI £48 million to £164 million saving, p=0.001)

Original publication

Cost-effectiveness of digoxin versus beta blockers in permanent atrial fibrillation: the Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF) randomised trial. Heart. Published 16 January 2025. doi:10.1136/heartjnl-2024-324761

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.